Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.75 |
| ▸ | CTSC | P53634 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL695411 | 0.99 | CTSS (0.74) | CTSSCTSCCTSLCTSB | |
| SCHEMBL15194059 | 0.88 | CTSS (0.70) | CTSSCTSCCTSLCTSB | |
| SCHEMBL696004 | 0.86 | CTSS (1.00) | CTSSCTSCCTSLCTSB | |
| SCHEMBL695956 | 0.86 | CTSS (1.00) | CTSSCTSCCTSLCTSB | |
| Hydrochloric Acid SCHEMBL695373 | 0.85 | CTSS (0.98) | CTSSCTSCCTSLCTSB | |
| SCHEMBL697326 | 0.83 | CTSS (0.64) | CTSSCTSCCTSLCTSB | |
| SCHEMBL697725 | 0.82 | CTSS (0.74) | CTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL694102 | 0.82 | CTSS (0.72) | CTSSCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL694517 | 0.81 | CTSS (0.71) | CTSSCTSCCTSLCTSB | |
| SCHEMBL697094 | 0.81 | CTSS (0.71) | CTSSCTSCCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | claimed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| EP-2814822-B1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| WO-2013120921-A9 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| EP-2814822-A1 | NOVEL PYRROLIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-8802665-B2 | Pyrrolidine derivatives | GENENTECH, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013120921-A1 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, ADCYAP1R1, AVPR1A | CTSS 2804/4885CTSC 2623/4885CTSL 1396/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CTSS 1542/4885CTSC 606/4885CTSL 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.